Prognostic Role of High Stathmin 1 Expression in Patients with Solid Tumors: Evidence from a Meta-Analysis.

Abstract

BACKGROUND/AIMS:

Several recent studies have demonstrated that Stathmin 1expression may be closely associated with prognosis in patients with various types of cancers. In the present study, we conducted a meta-analysis of all available studies in the English literature to assess the prognostic value of Stathmin 1expression in patients with solid cancers.

METHODS:

The online databases PubMed, Embase, and Web of Science were searched for literature regarding Stathmin 1 and its association with patient outcomes associated with solid cancers.

RESULTS:

A total of 23 articles including 26 studies that contained 5 335 patients were retrieved and analyzed. Our results indicated that high Stathmin 1 expression yielded a worse overall survival (OS) (hazard ratio [HR] = 2.17, 95% confidence interval [CI]: 1.81-2.60), disease-free survival (DFS) (HR = 2.46, 95% CI: 2.00-3.02), disease-specific survival (DSS) (HR = 1.98, 95% CI: 1.58- 2.47) and progression-free survival (PFS)/recurrence-free survival (RFS) (HR = 2.09, 95% CI: 1.51-2.89). Furthermore, the association of high Stathmin 1 expression with poor survival was significant even for sub-group analyses of different tumor types, ethnicities, methods used to calculate HRs, detected methods, and analysis types.

CONCLUSION:

In summary, this meta-analysis determined that high Stathmin 1 expression is associated with poor prognosis in patients with solid cancers and expression of this protein could be a clinically useful prognostic biomarker.

• Authors: Qingyan Mao, Zhen Chen, Kun Wang, Renfang Xu, Hao Lu, Xiaozhou He
• Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology (Cell Physiol Biochem) Vol. 50 Issue 1 Pg. 66-78 ( 2018) ISSN: 1421-9778 [Electronic] Germany
• PMID: 30278466 (Publication Type: Journal Article, Meta-Analysis)
• Copyright: © 2018 The Author(s). Published by S. Karger AG, Basel.

Chemical References

• Biomarkers, Tumor
• STMN1 protein, human
• Stathmin

Topics

• Biomarkers, Tumor (metabolism)
• Databases, Factual
• Disease-Free Survival
• Humans
• Neoplasms (metabolism, mortality, pathology)
• Prognosis
• Proportional Hazards Models
• Stathmin (genetics, metabolism)
• Survival Rate